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Abstract Tertiary structure models of Interleukin-6 were 
constructed using a routine prediction method based on the X-
ray crystal structures of granulocyte colony-stimulating factor 
(GCSF) and leukemia inhibitory factor (LIF). The models were 
evaluated with the aid of the sequence-structure compatibility 
(3D-1D) method program compass and NMR experimental 
information. The model constructed from GCSF gained higher 
scores on compass examination than did that from LIF, and the 
NOE data [Nishimura et al. (1996) Biochemistry 35, 273-281] 
also turned to be more consistent with the former model. 
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1. Introduction 
In modern molecular biology and related sciences and tech-
nologies, it is a matter of key importance to predict the three-
dimensional structure of a protein which is precise enough to 
be used as a working hypothesis for studying structure-func-
tion relationships, and it should be carried out as soon as its 
one-dimensional sequence has been determined. We have been 
trying to develop a strategic technique which is sufficiently 
able to distinguish a better stereo model from the others 
and which is easy to use for a wide range of proteins. 
Interleukin-6 (IL-6) was chosen as a test case in our present 
study. IL-6 is a soluble protein factor possessing 184 amino 
acids, which was cloned as a B cell stimulatory factor which 
induces the final stage of differentiation of B cells to antibody 
producing cells [1]. Subsequently, it was demonstrated that 
IL-6 is a multifunctional cytokine which affects not only im-
mune systems but also hematopoietic systems, nervous sys-
tems, endocrines, etc. [2]. In particular, recent studies using 
transgenic and knockout mice suggest that IL-6 plays an im-
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portant role in various defense systems during the acute phase 
and its overproduction is concerned with various diseases and 
a morbid state [3-5]. As IL-6 acts in conjunction with two 
kinds of receptors for gp80 and gpl30 on the target cell sur-
face, knowledge of its three-dimensional structure is of key 
significance in the development of IL-6 agonists and antago-
nists. It has been proven, e.g. from CD results, that the sec-
ondary structure of IL-6 is all a-helical and it was postulated 
to possess four helices bundled in an up-up-down-down type 
of topology [6]. Many cytokines have been demonstrated to 
adopt this folding, however, there is little sequence identity 
with IL-6. 
Therefore, tertiary structure prediction for IL-6 cannot be 
achieved with the conventional homology modeling method 
based on amino acid sequence information alone. Conse-
quently, reference proteins (to be used for modeling) should 
be chosen for similarity of their biological activity to and 
structural compatibility with IL-6, and finally two reference 
proteins were chosen among PDB coordinate sets. It has been 
proposed, based on cysteine positional conservation and sim-
ilar biological activity, that the three-dimensional structure of 
IL-6 closely resembles that of GCSF (granulocyte colony-
stimulating factor). Accordingly, rat IL-6 was modeled by 
Hammacher et al. [7] after human GCSF, and human IL-6 
was modeled by Ehlers et al. [8] and Savino et al. [9] after 
human and bovine GCSF, respectively. Both of these refer-
ence GCSF only. We propose here that not only GCSF but 
also LIF (leukemia inhibitory factor) can be used as a refer-
ence protein for IL-6, after searching PDB with the sequence-
structure compatibility method (3D/1D) program compass 
[10,11]. In this study, two IL-6 models (one based on GCSF 
and the other according to LIF) are being constructed and 
evaluation of these models is being carried out using NMR 
experimental information (NOE data), a 3D/1D method, and 
energy calculations. 
2. Methods 
The alignment shown in Fig. 1 was used. The procedure for our 
homology modeling is shown in Fig. 2. The software package BIO-
CES[E] was used for the modeling. The modeled structures were 
evaluated with the 3D/1D method compass, which is equipped with 
a structural library containing 617 structures. They were selected from 
a total of 3451 proteins in Protein Data Bank release 72 (April, 1995), 
such that the sequence identity to one another was less than 50% [11]. 
The compass search was performed by adding the two models to the 
structural library. For optimization calculation, Kopt with AMBER's 
parameter and CHARMm with the CHARM parameter were used. 
Aro and kai were employed in order to superimpose two proteins. 
PROCHECK [12] was used for checking the accuracy of the coordi-
nates. 
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Fig. 1. Sequence alignment for human IL-6 with 184 residues. The single-letter amino acid code has been used. Gaps in the sequences due to 
the alignment are represented (-). Helical regions are IBGC 18^6 (helix A), 79-100 (helix B), 109-133 (helix C), 156-182 (helix D), 51-55 (he-
lix E). ILKI 21^t8 (helix A), 76-104 (helix B), 109-135 (helix C), and 156-178 (helix D). The indicated percentage shows the sequence homol-
ogy calculated from the number of residues in h-IL-6 that are the same as those in b-GCSF or m-LIF. (Upper) Amino acid sequence of human 
IL-6 and bovine GCSF; (lower) amino acid sequence of human IL-6 and mouse LIF. 
3. Results and discussion 
3.1. Choice of reference proteins 
Bovine GCSF was chosen, as it was judged from the results 
with compass that its tertiary structure has the best compati-
bility with human IL-6 as an all cc-helical protein. The scores 
are listed in Table 1, in which the 10 best proteins are listed 
together with the IL-6 models, IBGC and ILKI. Also shown 
in Table 1 is one of the reference proteins, ILKI, which was 
ranked 100th with a low compatibility score in magnitude. 
The other reference protein, IBGC, was found within the 
best 10. Since IL-6 has been demonstrated, e.g. by using 
CD data, to possess a secondary structure consisting mainly 
of a-helices [6], those proteins having the folding pattern of al 
p mixtures were excluded. There are two all-a proteins listed 
in Table 1, i.e. GCSF and endonuclease, which were consid-
ered to be appropriate references, and rough models of IL-6 
were constructed (data not shown) from the PDB data. Based 
Table 1 
Compatibility of the human IL-6 sequence with known structures; 617 structures were compared and sorted in order of their compatibility 
scores 
Rank Structure PDB code Compatibility score Folding type 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
-
100 
Isocitrate dehydrogenase 
Endo-1,4-|3-D-glucanase 
Purine nucleoside phosphorylase 
IL-6 model based on b-GCSF 
Uridylate kinase 
Granulocyte colony-stimulating factor (GCSF) 
Pyruvate kinase 
Dethiobiotin synthase 
Type/Ill chloramphenicol acetyltransferase 
Malate dehydrogenase 
Endonuclease 
IL-6 model based on m-LIF 
Leukemia inhibitory factor (LIF) mouse 
7ICD 
1TML 
1ULA 
IBGC 
1UKZ 
IBGC 
1PKN 
1DTS 
3CLA 
1HLP 
1ABK 
ILKI 
ILKI 
-2.47 
-2.27 
-2.16 
-2.14 
-2.02 
-1.93 
-1.88 
-1.86 
-1.86 
-1.85 
-1.75 
-1.61 
-1.02 
alpha/beta 
alpha/beta 
alpha/beta 
all alpha 
alpha/beta 
all alpha 
alpha/beta 
alpha/beta 
alpha/beta 
alpha/beta 
all alpha 
all alpha 
all alpha 
The best 10 structures are listed together with IL-6's models, IBGC and ILKI, and reference proteins, IBGC and ILKI. 
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human 1L6-X3CSF 
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optimization of the models 
to relieve strain 
check the models 
3D/1D, energy, NMR-NOE.PROCHECK 
Fig. 2. Flow diagram of our homology modeling procedures. 
Table 2 
Compatibility of the bovine IL-6 sequence with known structures; 
scores 
Rank Structure 
1 Leukemia inhibitory factor (LIF) mouse 
2 Endo-l,4-|3-D-glucanase 
3 Isocitrate dehydrogenase 
4 Annexin V rat 
5 Methane monooxygenase hydrolase 
6 Deoxyribonuclease I rabbit 
7 Cytochrome P450 (BM-3) 
8 Renin mouse 
9 EcoRI endonuclease 
10 L-Lactate dehydrogenase 
41 Granulocyte colony-stimulating factor (GCSF) 
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on the consideration that it should have S-S bridges, the dis-
tances between the Cys C-a atoms of the corresponding res-
idues were judged to be too long for the endonuclease-based 
model. Therefore, it is not suitable as a reference protein, 
leaving only GCSF. 
When the compass search was performed with the bovine 
IL-6 sequence, instead of that of human IL-6, the results 
shown in Table 2 were obtained, where 1LKI (mouse LIF) 
was found to be the best whereas IBGC was not good, being 
ranked 41st. Considering that the sequence identity between 
human and bovine IL-6 is 50%, the 3D/1D compatibility 
method appears to be very sensitive to the input sequence. 
Mouse LIF also combines with gpl30 in the same manner 
as IL-6 does, in other words, gpl30 can be shared as a re-
ceptor. It is also remarkable that LIF and IL-6 belong to the 
same long-chain-type classification which was assigned by 
Sprang and Bazan [13]. Along with these facts, it is reasonable 
to employ the three-dimensional structure of mouse LIF as 
another reference structure. 
3.2. Modeling 
Using the tertiary structures of GCSF and LIF registered in 
PDB, IL-6 modeling was performed. The alignment used is 
illustrated in Fig. 1. The alignment of GCSF and IL-6 deter-
mined here is consistent with those obtained by others includ-
ing Bazan [14]. In the alignment of GCSF and IL-6, the posi-
tions of Cys residues forming S-S bridges were useful in the 
arrangement. 
For the alignment between human IL-6 and mouse LIF in 
Fig. 1, the alignment between bovine IL-6 and mouse LIF was 
first determined using the 3D/1D method, and then bovine IL-
6 was used to replace human IL-6 according to sequence 
homology. 
3.3. Features of the models 
The two IL-6 models are illustrated in Fig. 3. IBGC is the 
model of human IL-6 based on bovine GCSF, and ILKI is 
that based on mouse LIF. Helix A of IBGC is straight, how-
ever, that of ILKI has a kink, which is because the original 
structure of LIF has an internal hydrogen bond between Leu-
40 (O) and Ser-43 (N). Although IL-6 also has Ser-36 in helix 
A, it was not possible to match it with Ser-43 of LIF in the 
alignment as the resulting model contains the destroyed hy-
drophobic core. There is no reason for the presence of a kink 
in the helix A of ILKI as the Ser residue has no possible 
internal hydrogen bond partner within the helix. The positions 
structures were compared and sorted in order of their compatibility 
PDB code 
ILKI 
1TML 
7ICD 
2RAN 
1MMOB 
1ATNA 
2HPDA 
1SMRA 
1ERLA 
1LDNA 
IBGC 
Compatibility score 
-2.23 
-2.20 
-2.19 
-1.92 
-1.90 
-1.83 
-1.79 
-1.78 
-1.76 
-1.75 
-1.39 
Folding type 
all alpha 
alpha/beta 
alpha/beta 
alpha/beta 
all alpha 
alpha/beta 
alpha/beta 
alpha/beta 
alpha/beta 
alpha/beta 
all alpha 
The best 10 structures are listed together with reference protein, IBGC. 
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Fig. 3. Homology model of human IL-6 based on bovine GCSF (IBGC, white). Homology model of human IL-6 based on mouse LIF (ILKI, 
greenish yellow tube). A pair of yellow balls represents S-S bond (Cys-CA atoms). 
of helices B and C match between the two models. However, 
the position of helix D slips by one roll to each of the others. 
The wheel models [15] are shown in Fig. 4, which is of help 
in gaining knowledge of the inter-helical interactions and 
nearest neighbors therein. This is lateral information, the ver-
tical relationship among the four helices being shown in Fig. 
5. When two models were both superimposed on helices B and 
C, it was recognized there is one roll slip in helix A between 
the models. In helix D, which has a different relative gradient 
from the other helices, there is also one roll slip between the 
two models. No major difference between the models was 
found for helices B and C, however, one or two residue slips 
can be recognized. 
As shown here, the two models have different manners of 
inter-helical packing, so one of those should be incorrect. 
3.4. Evaluation by compass and energy calculations 
The results on the models obtained by evaluation using 
Table 3 
Energy values in kj calculated with CHARMm for 16R-184M of IBGC and ILKI 
Bond energy 
Angle energy 
Regular dihedral energy 
Improper dihedral energy 
Lennard-Jones energy 
Electrostatic energy 
Constraints, other 
Total energy 
IBGC 
Initial 
713.94 
4138.89 
1 894.20 
661.81 
6.355£4-ll 
-26723.88 
26723.85 
6.354£+ll 
Minimized 
502.95 
4024.98 
1 836.59 
875.04 
- 3 526.01 
-30226.51 
-0.004186 
-26512.96 
ILKI 
Initial 
84539.96 
4813.45 
1981.16 
4436.88 
2.534£4-ll 
- 2 1 866.42 
4720.57 
2.534£+ll 
Minimized 
541.55 
2691.80 
2232.08 
822.36 
-1209.88 
-237729.09 
0.002093 
-22651.18 
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Fig. 4. Wheel plots for models IBGC and ILKI which show lateral information for inter-helical arrangement. 
compass are given in Table 1. The data show that both models 
gained higher scores compared with each reference protein. 
Furthermore, IBGC was evaluated as being superior to 
ILKI. The compass scores for residues are given separately 
in Fig. 6, in which it can be seen that the scores of the helices 
are better than those of the loops. It also shows that the two 
models have good helical backbones. 
Each energy was calculated using CHARMm, where the 
numbers of residues were adjusted to be equal (16R-184M) 
for both models, and the values obtained are listed in Table 3, 
which shows that the total energy of IBGC is lower than that 
Table 4 
NOE reproducibility of two models 
Residue pairs 
Tyr-100 
Val-115 
Ile-29 
Ile-36 
Ile-36 
Phe-94 
Val-96 
Tyr-97 
He-166 
Phe-170 
Leu-174 
Leu-167 
Phe-170 
Phe-170 
Leu-151 
Leu-151 
IBGC 
B 
A 
A 
A 
A 
A 
C 
A 
ILKI 
C 
C 
C 
C 
A 
A 
C 
C 
Definition of proximity, in which nearest atom pairs other than hy-
H. Sumikawa et al.lFEBS Letters 404 (1997) 234-240 
of ILKI. This is thought to be due mainly to its lower electro-
static and Lennard-Jones energy terms. 
3.5. Evaluation by NOE 
The models were also evaluated with distance information 
obtained from NMR investigation [16]. The distances were 
calculated for the pairs of residues in the models in which 
NOE cross-peaks were observed in the experiment. The results 
are shown in Table 4. IBGC showed good agreement with the 
Fig. 5. Vertical relationship among four helices in models IBGC 
and ILKI. Solid lines define experimental NOE pairs. 
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A B C D 
7(b) l _ _ J 1 I C — ^ 3 £ Z = 
0 50 100 150 200 
residue numbers 
Fig. 6. 3D/1D score for each residue. ( ) IBGC, (—) ILKI. Box 
shows helical regions; (a) IBGC, (b) ILKI. 
NOE data, except for the pair consisting of Val-96 and Leu-
151. The distance from Val-96 (CA) to Leu-151 (N) in the 
IBGC model is 1.16 nm, however, as Leu-151 is located on 
the loop, this inconsistency can be avoided by adjusting the 
orientation of its side chain. ILKI showed worse agreement 
with the NOE data; only two pairs could be reproduced (Tyr-
94-Phe-170; Ile-36-Phe-170). In their paper, there were two 
leucines with unknown residue numbers, i.e. Leu-X and Leu-
Y. NOE cross-peaks were observed for two residue pairs, Leu-
X-Tyr-100 and Leu-X-Phe-105 therein. Both IBGC and ILKI 
showed that Leu-X was determined to be Leu-101 in the 
present study. They also showed cross peaks between three 
residue pairs, Leu-Y-Phel70, Leu-Y-Phel73 and Leu-Y-
Leul74. Although IBGC was able to show that Leu-Y was 
determined to be Leu-91, ILKI could not demonstrate any-
thing. 
As shown above, by constructing two models of IL-6 based 
on two known protein structures of GCSF and LIF, it was 
judged from compass scores, energy values, and NOE repro-
ducibility that the GCSF model is superior to the LIF model. 
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